-
Abstract Number: 1409
Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs
-
Abstract Number: 1410
Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis
-
Abstract Number: 1411
Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy
-
Abstract Number: 1412
Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study
-
Abstract Number: 1413
Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy
-
Abstract Number: 1414
Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab
-
Abstract Number: 1415
Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis
-
Abstract Number: 1416
B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis
-
Abstract Number: 1417
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry
-
Abstract Number: 1418
Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry
-
Abstract Number: 1419
Cost-per-Responder Analysis of Sarilumab for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (RA)
-
Abstract Number: 1420
Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
-
Abstract Number: 1421
Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results
-
Abstract Number: 1422
Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA
-
Abstract Number: 1423
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
- « Previous Page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- …
- 198
- Next Page »